×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | 3.25 | -4.52 | NA | -18.44 | 0 | |
| ALIVUS LIFE SCIENCES LIMITED | 6,596.33 | 1,418.68 | 6,495.45 | 11.55 | 12,466 | 25.7 |
| GRANULES INDIA LTD. | 7,985.11 | 940.54 | 7,680.26 | 3.88 | 11931 | 24.8 |
| Vijaya Diagnostic Centre Limit | 1822.68 | 383.89 | 1748.45 | 3.73 | 11498 | 76.2 |
Glenmark Life Sciences Limited, with Security Code 543322, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 540.7 | 621.3 | 578.5 | 595.4 | 572.8 | 536.6 | 588.6 | 506.9 | 641.8 | 649.5 |
| Expenses | 395.3 | 414.9 | 385.3 | 428.3 | 400.2 | 395.2 | 429.1 | 372.5 | 451.5 | 451.1 |
| Operating Profit | 145.5 | 206.4 | 193.2 | 167.1 | 172.6 | 141.4 | 159.5 | 134.4 | 190.3 | 198.5 |
| OPM % | 26.9% | 33.22% | 33.39% | 28.06% | 30.12% | 26.36% | 27.09% | 26.51% | 29.65% | 30.56% |
| Other Income | 6.6 | 2.8 | 1.9 | 5.4 | 1.7 | 3.1 | 5.5 | 8.5 | 10.5 | 10.1 |
| Interest | 0.2 | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.5 | 1.3 |
| Depreciation | 10.8 | 11.5 | 12.6 | 13.1 | 13.2 | 14.5 | 14.4 | 15.1 | 15.2 | 16.0 |
| Profit before tax | 141.1 | 197.6 | 182.0 | 158.9 | 160.7 | 129.7 | 150.2 | 127.5 | 185.1 | 191.3 |
| Tax % | -25.6% | -25.9% | -25.6% | -25.3% | -26.1% | -24.5% | 25.8% | 25.2% | 26% | -25.8% |
| Net Profit | 105.0 | 146.4 | 135.5 | 118.7 | 118.8 | 97.9 | 111.5 | 95.3 | 137.0 | 141.9 |
| EPS in Rs | 8.57 | 11.94 | 11.05 | 9.69 | 9.67 | 7.97 | 9.08 | 7.75 | 11.14 | 0 |
No Consolidated data available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 9% |
| 3 Years: | 4% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 37% |
| 1 Year: | 34% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 37% |
| 1 Year: | 34% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|